Bal, S., Costa, L., Bahlis, N., Htut, M., Nadeem, O., Patel, K., Solomon, S., Davis, J., Guo, Z., Hsu, K., Hu, H., Juluri, K. R., Katz, J., Pulham, T., Ziyad, S., Mailankody, S. (2025). Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. https://doi.org/10.1182/blood-2025-5807